Arthur J. Gallagher [AJG] Downgraded to Neutral at Goldman Sachs
Goldman Sachs took its Arthur J. Gallagher [AJG] rating to the equivalent of Neutral from Buy, and the price target to $129.0 from $123, in a research note dated 2021-01-08. That figure represents around a 5.41% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with Evercore ISI’s […]
Insider Selling: Arrowhead Pharmaceuticals Inc. [ARWR] GC Sells 25,000 Shares Worth $1,810,346
On Jan. 06, O’Brien Patrick divested U.S. $1,810,346 in shares of Arrowhead Pharmaceuticals Inc.. The GC sold 25,000 shares at a price per share of $72.41. The transaction decreased this specific insider’s holdings to 293,375 shares worth around $23.31 million at present. Another 30,625 shares were sold by Myszkowski Kenneth Allen, for more than $2,218,477 […]
Here is the reason why Jaguar Health, Inc. (NASDAQ: JAGX) shares are on the up today
Jaguar Health, Inc. (NASDAQ:JAGX) stock is thriving today as it soared over 44% to reach $3.8 as it revealed in an announcement that the 28-day preclinical test in dogs has begun, January 6, 2021, to support the development of lechlemer, the plant-based drug candidate of Jaguar Health’s wholly-owned subsidiary, Napo Pharmaceuticals, for the relief of […]
BMO Capital upgrades Life Storage [LSI] to Outperform and price target to $140
BMO Capital took its Life Storage [LSI] rating to the equivalent of Outperform from Market Perform, and the price target to $140, in a research note dated 2021-01-08. That figure represents around a 21.55% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Raymond James’s analysts upgrading the […]
RenaissanceRe Holdings [RNR] gets an upgrade to a Buy from Goldman Sachs
Goldman Sachs took its RenaissanceRe Holdings [RNR] rating to the equivalent of Buy from Neutral, and the price target to $199.0, in a research note dated 2021-01-08. That figure represents around a 19.72% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with Citigroup’s analysts assigning the shares […]
HC Wainwright & Co. maintains Krystal Biotech [KRYS] at Buy rating with a $84 price target
HC Wainwright & Co. maintained its Krystal Biotech [KRYS] rating to the equivalent of Buy but changed the price target to $84.0 from $68, in a research note dated 2021-01-08. That figure represents around a 28.74% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with Evercore ISI’s […]
Insider Selling Report: Colfax Corporation [CFX]’s Pres, CEO, Trerotola Matthew L., Sells 22,039 Shares
On Jan. 05, Trerotola Matthew L. divested U.S. $840,181 in shares of Colfax Corporation. The Pres, CEO sold 22,039 shares at a price per share of $38.12. The transaction decreased this specific insider’s holdings to 200,967 shares worth around $8.16 million at present. UBS took its Colfax Corporation [CFX] rating to the equivalent of a […]
Needham maintains Pacira BioSciences [PCRX] at Buy rating with a $76 price target
Needham maintained its Pacira BioSciences [PCRX] rating to the equivalent of Buy but changed the price target to $76.0 from $67, in a research note dated 2021-01-08. That figure represents around a 12.31% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Needham’s analysts reiterating the shares to […]
DocuSign Inc. [DOCU] Sees 5,800 Share Insider Sell From COO Olrich Scott V.
On Jan. 06, Olrich Scott V. divested U.S. $1,304,252 in shares of DocuSign Inc.. The COO sold 5,800 shares at a price per share of $224.87. The transaction decreased this specific insider’s holdings to 208,746 shares worth around $49.9 million at present. Piper Sandler took its DocuSign Inc. [DOCU] rating to the equivalent of an […]
SVB Leerink lowers Myovant Sciences [MYOV] rating to Market Perform and sets price target at $28
SVB Leerink took its Myovant Sciences [MYOV] rating to the equivalent of Market Perform from Outperform, and the price target to $28.0 from $30, in a research note dated 2021-01-08. That figure represents around a 11.02% premium from where the company’s shares closed on Thursday. Meanwhile, Goldman had launched its coverage on MYOV with “Buy”, […]
